OliX Pharmaceuticals, Inc (KOSDAQ:226950)

South Korea flag South Korea · Delayed Price · Currency is KRW
185,300
-11,200 (-5.70%)
Apr 28, 2026, 3:30 PM KST
269.12%
Market Cap 3.76T
Revenue (ttm) 14.67B
Net Income (ttm) -15.74B
Shares Out 20.30M
EPS (ttm) -800.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 256,869
Average Volume 285,569
Open 188,900
Previous Close 196,500
Day's Range 182,200 - 190,000
52-Week Range 34,500 - 217,000
Beta 0.56
RSI 54.96
Earnings Date Mar 27, 2026

About OliX Pharmaceuticals

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226950
Full Company Profile

Financial Performance

In 2025, OliX Pharmaceuticals's revenue was 14.67 billion, an increase of 158.35% compared to the previous year's 5.68 billion. Losses were -15.74 billion, -61.28% less than in 2024.

Financial Statements

News

There is no news available yet.